Active surveillance of adverse events following the first dose of COVID-19 vaccination – Oxford–AstraZeneca (Covishield) vaccine
Background: COVID-19 vaccines have been the most rapidly developed vaccines in history and consequently, fears of its safety and efficacy intrigue the minds of the common man. Aims: This study was intended to determine the adverse events following COVID-19 vaccination and thereby reduce vaccine hesi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Saudi Journal for Health Sciences |
| Subjects: | |
| Online Access: | http://www.saudijhealthsci.org/article.asp?issn=2278-0521;year=2022;volume=11;issue=2;spage=104;epage=109;aulast= |
| _version_ | 1811211184713498624 |
|---|---|
| author | Sangeetha Merrin Varghese Grace Mary John Geomcy George Linda Jacob Mammen Paul Arun Sachu Abel K Samuel Johnson George Mateethra Chandy |
| author_facet | Sangeetha Merrin Varghese Grace Mary John Geomcy George Linda Jacob Mammen Paul Arun Sachu Abel K Samuel Johnson George Mateethra Chandy |
| author_sort | Sangeetha Merrin Varghese |
| collection | DOAJ |
| description | Background: COVID-19 vaccines have been the most rapidly developed vaccines in history and consequently, fears of its safety and efficacy intrigue the minds of the common man. Aims: This study was intended to determine the adverse events following COVID-19 vaccination and thereby reduce vaccine hesitancy in the people. Methods and Materials: An active vaccine safety surveillance study was carried out on health-care workers of a tertiary care center in Central Kerala using a prestructured interview schedule documenting a description of adverse events following immunization (AEFI), time of occurrence, management and outcome of AEFI, knowledge about AEFIs, and fear of COVID-19 vaccination. A telephonic survey was carried out on 475 randomly selected COVID vaccine beneficiaries. Results: Overall, 86% of the participants reported at least one postvaccination symptom. Fever (51.8%), injection-site pain (46.9%), headache (29.3%), myalgia (28.4%), and fatigue/tiredness (25.1%) were the most common symptoms. None of the symptoms were severe/serious to warrant hospital admission. Side effects were more common in females (P = 0.003) and reactogenicity of the COVID-19 vaccine decreased with advancing age (P = 0.001). The vaccine did not have any difference in side effects among those who had previous COVID-19 infection. Conclusion: This study shows that COVID vaccines are safe in the Indian population and the side effects are similar to any other vaccine. It may help to dispel any fear and misinformation regarding COVID-19 vaccination and thus maximize the benefit of the nationwide immunization program. |
| first_indexed | 2024-04-12T05:08:32Z |
| format | Article |
| id | doaj.art-94a14ebdb7984980a843582d206faa07 |
| institution | Directory Open Access Journal |
| issn | 2278-0521 |
| language | English |
| last_indexed | 2024-04-12T05:08:32Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Saudi Journal for Health Sciences |
| spelling | doaj.art-94a14ebdb7984980a843582d206faa072022-12-22T03:46:49ZengWolters Kluwer Medknow PublicationsSaudi Journal for Health Sciences2278-05212022-01-0111210410910.4103/sjhs.sjhs_59_21Active surveillance of adverse events following the first dose of COVID-19 vaccination – Oxford–AstraZeneca (Covishield) vaccineSangeetha Merrin VargheseGrace Mary JohnGeomcy GeorgeLinda JacobMammen PaulArun SachuAbel K Samuel JohnsonGeorge Mateethra ChandyBackground: COVID-19 vaccines have been the most rapidly developed vaccines in history and consequently, fears of its safety and efficacy intrigue the minds of the common man. Aims: This study was intended to determine the adverse events following COVID-19 vaccination and thereby reduce vaccine hesitancy in the people. Methods and Materials: An active vaccine safety surveillance study was carried out on health-care workers of a tertiary care center in Central Kerala using a prestructured interview schedule documenting a description of adverse events following immunization (AEFI), time of occurrence, management and outcome of AEFI, knowledge about AEFIs, and fear of COVID-19 vaccination. A telephonic survey was carried out on 475 randomly selected COVID vaccine beneficiaries. Results: Overall, 86% of the participants reported at least one postvaccination symptom. Fever (51.8%), injection-site pain (46.9%), headache (29.3%), myalgia (28.4%), and fatigue/tiredness (25.1%) were the most common symptoms. None of the symptoms were severe/serious to warrant hospital admission. Side effects were more common in females (P = 0.003) and reactogenicity of the COVID-19 vaccine decreased with advancing age (P = 0.001). The vaccine did not have any difference in side effects among those who had previous COVID-19 infection. Conclusion: This study shows that COVID vaccines are safe in the Indian population and the side effects are similar to any other vaccine. It may help to dispel any fear and misinformation regarding COVID-19 vaccination and thus maximize the benefit of the nationwide immunization program.http://www.saudijhealthsci.org/article.asp?issn=2278-0521;year=2022;volume=11;issue=2;spage=104;epage=109;aulast=adverse eventscovid-19 vaccinationsafety |
| spellingShingle | Sangeetha Merrin Varghese Grace Mary John Geomcy George Linda Jacob Mammen Paul Arun Sachu Abel K Samuel Johnson George Mateethra Chandy Active surveillance of adverse events following the first dose of COVID-19 vaccination – Oxford–AstraZeneca (Covishield) vaccine Saudi Journal for Health Sciences adverse events covid-19 vaccination safety |
| title | Active surveillance of adverse events following the first dose of COVID-19 vaccination – Oxford–AstraZeneca (Covishield) vaccine |
| title_full | Active surveillance of adverse events following the first dose of COVID-19 vaccination – Oxford–AstraZeneca (Covishield) vaccine |
| title_fullStr | Active surveillance of adverse events following the first dose of COVID-19 vaccination – Oxford–AstraZeneca (Covishield) vaccine |
| title_full_unstemmed | Active surveillance of adverse events following the first dose of COVID-19 vaccination – Oxford–AstraZeneca (Covishield) vaccine |
| title_short | Active surveillance of adverse events following the first dose of COVID-19 vaccination – Oxford–AstraZeneca (Covishield) vaccine |
| title_sort | active surveillance of adverse events following the first dose of covid 19 vaccination oxford astrazeneca covishield vaccine |
| topic | adverse events covid-19 vaccination safety |
| url | http://www.saudijhealthsci.org/article.asp?issn=2278-0521;year=2022;volume=11;issue=2;spage=104;epage=109;aulast= |
| work_keys_str_mv | AT sangeethamerrinvarghese activesurveillanceofadverseeventsfollowingthefirstdoseofcovid19vaccinationoxfordastrazenecacovishieldvaccine AT gracemaryjohn activesurveillanceofadverseeventsfollowingthefirstdoseofcovid19vaccinationoxfordastrazenecacovishieldvaccine AT geomcygeorge activesurveillanceofadverseeventsfollowingthefirstdoseofcovid19vaccinationoxfordastrazenecacovishieldvaccine AT lindajacob activesurveillanceofadverseeventsfollowingthefirstdoseofcovid19vaccinationoxfordastrazenecacovishieldvaccine AT mammenpaul activesurveillanceofadverseeventsfollowingthefirstdoseofcovid19vaccinationoxfordastrazenecacovishieldvaccine AT arunsachu activesurveillanceofadverseeventsfollowingthefirstdoseofcovid19vaccinationoxfordastrazenecacovishieldvaccine AT abelksamueljohnson activesurveillanceofadverseeventsfollowingthefirstdoseofcovid19vaccinationoxfordastrazenecacovishieldvaccine AT georgemateethrachandy activesurveillanceofadverseeventsfollowingthefirstdoseofcovid19vaccinationoxfordastrazenecacovishieldvaccine |